Alpha Tau Medical Ltd., (DRTS): Price and Financial Metrics
GET POWR RATINGS... FREE!
DRTS Stock Price Chart Interactive Chart >
DRTS Price/Volume Stats
| Current price | $2.83 | 52-week high | $16.33 |
| Prev. close | $2.78 | 52-week low | $2.77 |
| Day low | $2.79 | Volume | 34,100 |
| Day high | $3.05 | Avg. volume | 71,775 |
| 50-day MA | $3.49 | Dividend yield | N/A |
| 200-day MA | $5.91 | Market Cap | 195.65M |
Alpha Tau Medical Ltd., (DRTS) Company Bio
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Latest DRTS News From Around the Web
Below are the latest news stories about ALPHA TAU MEDICAL LTD that investors may wish to consider to help them evaluate DRTS as an investment opportunity.
Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley BankJERUSALEM, March 12, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today issued the following statement on Silicon Valley Bank (SVB) in response to questions from investors and analysts. We maintain no accounts or other financial relationships with SVB, and we do not currently expect its closure to have any impact on our operations. About Alpha DaRT™ Alpha DaRT (Di |
Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update- Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March - - Received Health Canada approval to initiate a liver cancer feasibility trial - - Pursued supply chain expansion in Israel, the U.S. and Japan, including increases in radioactive license capacities - - Cash & equivalents balance of $105.4 million, with runway for at least two years - JERUSALEM, March 09, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Compa |
Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial-First two US patients with recurrent cutaneous squamous cell carcinoma have been treated at University Cancer Center in Houston, Texas -Up to 86 patients to be enrolled in the U.S., Canada, Europe and Israel to assess the efficacy and safety of intratumoral Alpha DaRT for the treatment of patients with recurrent cutaneous squamous cell carcinoma JERUSALEM, March 08, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innova |
Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem HeadquartersJERUSALEM, March 03, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the Israeli Ministry of Environmental Protection has granted the Company an amended radioactive license in the main manufacturing floor of its production facility in Jerusalem, increasing the maximum allowable amount of Thorium-228 for use and possession to produce Alpha DaRT so |
Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver MetastasesJERUSALEM, March 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has received authorization from Health Canada to proceed with a feasibility and safety study of Alpha DaRT in the treatment of liver metastases, subject to final approval by an institutional Research Ethics Board, which the Company expects to receive in the coming weeks. The |
DRTS Price Returns
| 1-mo | -9.58% |
| 3-mo | -12.38% |
| 6-mo | -51.54% |
| 1-year | -81.50% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -11.01% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...